The results indicate that the EPO level is relatively successful in predicting the mortality and re-hospitalization rates of CHF patients at end points within two years of follow-up (P<0.01), and NT-proBNP levels may also be used as a successful predictor. This evidence concerns the gene EPO and congestive heart failure.